Document

0000040545-20-000012.txt : 20200406 0000040545-20-000012.hdr.sgml : 20200406 20200406161917 ACCESSION NUMBER: 0000040545-20-000012 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200331 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200406 DATE AS OF CHANGE: 20200406 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENERAL ELECTRIC CO CENTRAL INDEX KEY: 0000040545 STANDARD INDUSTRIAL CLASSIFICATION: ELECTRONIC & OTHER ELECTRICAL EQUIPMENT (NO COMPUTER EQUIP) [3600] IRS NUMBER: 140689340 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-00035 FILM NUMBER: 20777204 BUSINESS ADDRESS: STREET 1: 5 NECCO STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 617-443-3000 MAIL ADDRESS: STREET 1: 5 NECCO STREET CITY: BOSTON STATE: MA ZIP: 02210 8-K 1 biopharmaproforma8-k.htm 8-K Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 31, 2020

General Electric Company

(Exact name of registrant as specified in its charter)




New York			001-00035	14-0689340
(State or other jurisdiction of incorporation)			(Commission File Number)	(IRS Employer Identification No.)

5 Necco Street	Boston,	MA		02210
(Address of principal executive offices)				(Zip Code)

(Registrant’s telephone number, including area code) (617) 443-3000

_______________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):



☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:



Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.06 per share	GE	New York Stock Exchange
Floating Rate Notes due 2020	GE 20E	New York Stock Exchange
0.375% Notes due 2022	GE 22A	New York Stock Exchange
1.250% Notes due 2023	GE 23E	New York Stock Exchange
0.875% Notes due 2025	GE 25	New York Stock Exchange
1.875% Notes due 2027	GE 27E	New York Stock Exchange
1.500% Notes due 2029	GE 29	New York Stock Exchange
7 1/2% Guaranteed Subordinated Notes due 2035	GE /35	New York Stock Exchange
2.125% Notes due 2037	GE 37	New York Stock Exchange



	Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
	Emerging growth company	☐
	If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.	☐

(1)

Item 2.01 Completion of Acquisition or Disposition of Assets.

On March 31, 2020, General Electric Company (the “Company” or “GE”) completed the sale of its BioPharma business in its Healthcare segment to Danaher Corporation (“Danaher”) for $21.4 billion ($21.1 billion of total consideration, reflecting $0.3 billion of working capital adjustments to the contractual price). The consideration consisted of $20.7 billion in cash and $0.4 billion of pension liabilities that were assumed by Danaher. The Company received cash of $20.3 billion on March 31st and an additional $0.4 billion on April 1st.

The unaudited pro forma financial information giving effect to the BioPharma sale transaction is filed herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits.

(b) Pro Forma Financial Information.

The following unaudited pro forma financial information of the Company is filed as Exhibit 99 to this Report on Form 8-K and is incorporated herein by reference:


•	Unaudited Pro Forma Condensed Consolidated Statement of Financial Position as of December 31, 2019.


•	Unaudited Pro Forma Condensed Consolidated Statement of Earnings (Loss) for the year ended December 31, 2019.


•	Notes to the Unaudited Pro Forma Condensed Consolidated Financial Statements.

(d) Exhibits.

99. General Electric Company Unaudited Pro Forma Condensed Consolidated Financial Statements.

104. The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

(2)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



		General Electric Company
		(Registrant)

Date: April 6, 2020		/s/ Thomas S. Timko
		Thomas S. Timko Vice President, Chief Accounting Officer and Controller

(3)

EX-99 2 biopharmaproformaexhib.htm EXHIBIT 99 Exhibit

Exhibit 99

GENERAL ELECTRIC COMPANY

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The following unaudited pro forma condensed consolidated statement of financial position as of December 31, 2019 is presented as if the BioPharma sale transaction, as described in the notes to these unaudited pro forma condensed consolidated financial statements, had occurred on December 31, 2019.

The unaudited pro forma condensed consolidated statement of earnings (loss) for the year ended December 31, 2019, is presented as if the BioPharma sale transaction had occurred on January 1, 2019. The estimated gain on sale in connection with the BioPharma sale transaction is reflected in the unaudited pro forma condensed statement of financial position within retained earnings. The estimated gain on sale is not reflected in the unaudited pro forma condensed consolidated statement of earnings (loss) as it does not have a continuing impact on GE’s results.

The unaudited pro forma condensed consolidated financial information is subject to the assumptions and adjustments described in the accompanying notes. These assumptions and adjustments are based on information presently available. Actual adjustments may differ materially from the information presented. The unaudited pro forma condensed consolidated financial statements are based on the historical financial statements of GE for each period presented and in the opinion of GE management, all adjustments and disclosures necessary for a fair presentation of the pro forma data have been made.

These unaudited pro forma condensed consolidated financial statements are presented for illustrative purposes only and are not necessarily indicative of the results of operations or financial condition that would have been achieved had events reflected been completed as of the dates indicated or of the results that may be obtained in the future. These unaudited pro forma condensed consolidated financial statements and the notes thereto should be read together with GE’s audited consolidated financial statements and the notes thereto as of and for the year ended December 31, 2019, and Management’s Discussion and Analysis included in GE’s Annual Report on Form 10-K for the year ended December 31, 2019.

(1)



UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
As of December 31, 2019 (in billions)	As Reported			BioPharma Pro Forma Adjustments				Pro Forma

Assets
Cash, cash equivalents and restricted cash	$	36.4		$	20.5		(a)	$	56.9
Investment securities	48.5			—				48.5
Current receivables	16.8			—				16.8
Inventories	14.1			—				14.1
Property, plant and equipment – net	43.3			—				43.3
Goodwill	26.7			—				26.7
Other intangible assets – net	10.7			—				10.7
Contract and other deferred assets	16.8			—				16.8
Assets of businesses held for sale	9.1			(8.7		)	(b)	0.4
All other assets	43.6			—				43.6
Total assets	$	266.0		$	11.8			$	277.8

Liabilities and equity
Short-term borrowings	$	22.1		$	—			$	22.1
Accounts payable, principally trade accounts	15.9			—				15.9
Progress collections and deferred income	20.5			—				20.5
Other GE current liabilities	15.8			1.3			(c)	17.1
Long-term borrowings	67.2			—				67.2
Insurance liabilities and insurance annuity benefits	39.8			—				39.8
Non-current compensation and benefits	31.7			—				31.7
Liabilities of businesses held for sale	1.7			(1.4		)	(b)	0.3
All other liabilities	21.6			0.1			(b)	21.7
Total liabilities	236.2			—				236.2

Preferred stock	—			—				—
Common stock	0.7			—				0.7
Accumulated other comprehensive income (loss) – net attributable to GE	(11.7		)	0.8			(d)	(11.0		)
Other capital	34.4			—				34.4
Retained earnings	87.7			10.9			(d)	98.7
Less common stock held in treasury	(82.8		)	—				(82.8		)
Total GE shareowners’ equity	28.3			11.7				40.0
Noncontrolling interests	1.5			—				1.5
Total equity	29.9			11.7				41.6
Total liabilities and equity	$	266.0		$	11.8			$	277.8

Amounts may not add due to rounding.

(2)



UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF EARNINGS (LOSS)
For the year ended December 31, 2019 (In billions; per-share amounts in dollars)	As Reported			BioPharma Pro Forma Adjustments (e)				Pro Forma

Revenues
Sales of goods	$	58.9		$	(3.1	)		$	55.8
Sales of services	28.5			(0.2		)		28.4
GE Capital revenues from services	7.7			—				7.7
Total revenues	95.2			(3.3		)		91.9

Costs and expenses
Cost of goods sold	48.4			(1.2		)		47.2
Cost of services sold	21.6			(0.1		)		21.5
Selling, general and administrative expenses	13.9			(0.6		)		13.3
Interest and other financial charges	4.2			—				4.2
Insurance losses and insurance annuity benefits	3.3			—				3.3
Goodwill impairment	1.5			—				1.5
Non-operating benefit costs	2.8			—				2.8
Other costs and expenses	0.5			—				0.5
Total costs and expenses	96.3			(2.0		)		94.3

Other income	2.2			(0.1		)		2.2
GE Capital earnings (loss) from continuing operations	—			—				—

Earnings (loss) from continuing operations before income taxes	1.1			(1.4		)		(0.2		)
Benefit (provision) for income taxes	(0.7		)	0.9			(f)	0.2
Earnings (loss) from continuing operations	0.4			(0.5		)		(0.1		)
Less net earnings (loss) attributable to noncontrolling interests	—			—				—
Preferred stock dividends	(0.5		)	—				(0.5		)
Net earnings (loss) from continuing operations attributable to GE common shareowners	$	—		$	(0.5	)		$	(0.5	)

Per-share amounts
Earnings (loss) from continuing operations
Diluted earnings (loss) per share	$	(0.01	)					$	(0.06	)
Basic earnings (loss) per share	$	(0.01	)					$	(0.06	)

Average equivalent shares (in millions)
Diluted	8,724							8,724
Basic	8,724							8,724

Amounts may not add due to rounding.

(3)

NOTES TO THE UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The following items resulted in adjustments in the unaudited pro forma condensed consolidated financial information:


a.	Adjustment represents $20.7 billion of cash consideration from the sale of our BioPharma business less $0.2 billion of estimated cash costs directly associated with the transaction.


b.	Adjustments represent the elimination of assets and liabilities held for sale attributable to BioPharma.


c.	Adjustment represents an increase in current tax liabilities of $1.4 billion as a result of the gain recognized on the sale of BioPharma offset by the elimination of $0.1 billion current tax liabilities attributable to BioPharma.


d.	Adjustments reflect the pre-tax gain on sale of BioPharma of $12.3 billion ($10.9 billion net of tax) calculated as follows:



(In billions)
Cash received (net of selling and other expenses)			$	20.5
Less: GE's carrying value in BioPharma ($8.7 billion assets less $1.4 billion liabilities)	$	7.3
Less: Release of accumulated other comprehensive loss (primarily foreign currency translation)	0.8
			$	8.1

Pro forma gain before income taxes			$	12.3
Benefit (provision) for income taxes			(1.4		)
Pro forma net gain on sale of BioPharma			$	10.9

Amounts may not add due to rounding.

The proforma net gain of $10.9 billion is reflected as an adjustment to retained earnings. This amount is based on historical information as of December 31, 2019 for GE’s carrying value and related amount of accumulated other comprehensive loss. The actual net gain will be based on GE’s carrying value in BioPharma as of March 31, 2020.


e.	Adjustments reflect the elimination of revenues, costs and expenses directly attributable to BioPharma. Adjustments do not include certain general corporate and segment overhead costs previously allocated to BioPharma that will have a continuing effect on GE post-closing.


f.	Adjustment reflects the estimated income tax effect of the pro forma adjustments at a statutory rate plus a discrete tax charge recognized by GE in 2019 directly related to BioPharma of $0.6 billion.

(4)

EX-101.SCH 3 ge-20200306.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 ge-20200306_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 ge-20200306_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 ge-20200306_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Entities [Table] Entities [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] Floating Rate Notes Due 2020 [Member] Floating Rate Notes Due 2020 [Member] Floating Rate Notes Due 2020 [Member] 0.375% Notes Due 2022 [Member] 0.375% Notes Due 2022 [Member] 0.375% Notes Due 2022 [Member] 1.250% Notes Due 2023 [Member] 1.250% Notes Due 2023 [Member] 1.250% Notes Due 2023 [Member] 0.875% Notes Due 2025 [Member] 0.875% Notes Due 2025 [Member] 0.875% Notes Due 2025 [Member] 1.875% Notes Due 2027 [Member] 1.875% Notes Due 2027 [Member] 1.875% Notes Due 2027 [Member] 1.500% Notes Due 2029 [Member] 1.500% Notes Due 2029 [Member] 1.500% Notes Due 2029 [Member] 7.5% Guaranteed Subordinated Notes Due 2035 [Member] 7.5% Guaranteed Subordinated Notes Due 2035 [Member] 7.5% Guaranteed Subordinated Notes Due 2035 [Member] 2.125% Notes Due 2037 [Member] 2.125% Notes Due 2037 [Member] 2.125% Notes Due 2037 [Member] Entity Information [Line Items] Entity Information [Line Items] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 7 ge-20200306_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT JSON 8 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "biopharmaproforma8-k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 10, "dts": { "calculationLink": { "local": [ "ge-20200306_cal.xml" ] }, "definitionLink": { "local": [ "ge-20200306_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "biopharmaproforma8-k.htm" ] }, "labelLink": { "local": [ "ge-20200306_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "ge-20200306_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "ge-20200306.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 36, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 8, "memberStandard": 1, "nsprefix": "ge", "nsuri": "http://www.ge.com/20200306", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "biopharmaproforma8-k.htm", "contextRef": "D2020Q1SD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.ge.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "biopharmaproforma8-k.htm", "contextRef": "D2020Q1SD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 9, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "ge_A0.375NotesDue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "0.375% Notes Due 2022 [Member]", "label": "0.375% Notes Due 2022 [Member]", "terseLabel": "0.375% Notes Due 2022 [Member]" } } }, "localname": "A0.375NotesDue2022Member", "nsuri": "http://www.ge.com/20200306", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "ge_A0.875NotesDue2025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "0.875% Notes Due 2025 [Member]", "label": "0.875% Notes Due 2025 [Member]", "terseLabel": "0.875% Notes Due 2025 [Member]" } } }, "localname": "A0.875NotesDue2025Member", "nsuri": "http://www.ge.com/20200306", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "ge_A1.250NotesDue2023Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.250% Notes Due 2023 [Member]", "label": "1.250% Notes Due 2023 [Member]", "terseLabel": "1.250% Notes Due 2023 [Member]" } } }, "localname": "A1.250NotesDue2023Member", "nsuri": "http://www.ge.com/20200306", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "ge_A1.500NotesDue2029Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.500% Notes Due 2029 [Member]", "label": "1.500% Notes Due 2029 [Member]", "terseLabel": "1.500% Notes Due 2029 [Member]" } } }, "localname": "A1.500NotesDue2029Member", "nsuri": "http://www.ge.com/20200306", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "ge_A1.875NotesDue2027Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.875% Notes Due 2027 [Member]", "label": "1.875% Notes Due 2027 [Member]", "terseLabel": "1.875% Notes Due 2027 [Member]" } } }, "localname": "A1.875NotesDue2027Member", "nsuri": "http://www.ge.com/20200306", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "ge_A2.125NotesDue2037Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.125% Notes Due 2037 [Member]", "label": "2.125% Notes Due 2037 [Member]", "terseLabel": "2.125% Notes Due 2037 [Member]" } } }, "localname": "A2.125NotesDue2037Member", "nsuri": "http://www.ge.com/20200306", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "ge_A7.5GuaranteedSubordinatedNotesDue2035Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "7.5% Guaranteed Subordinated Notes Due 2035 [Member]", "label": "7.5% Guaranteed Subordinated Notes Due 2035 [Member]", "terseLabel": "7.5% Guaranteed Subordinated Notes Due 2035 [Member]" } } }, "localname": "A7.5GuaranteedSubordinatedNotesDue2035Member", "nsuri": "http://www.ge.com/20200306", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "ge_FloatingRateNotesDue2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Floating Rate Notes Due 2020 [Member]", "label": "Floating Rate Notes Due 2020 [Member]", "terseLabel": "Floating Rate Notes Due 2020 [Member]" } } }, "localname": "FloatingRateNotesDue2020Member", "nsuri": "http://www.ge.com/20200306", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.ge.com/role/CoverPage" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover Page	Mar. 31, 2020
Entity Information [Line Items]
Document Type	8-K
Document Period End Date	Mar. 31, 2020
Entity Registrant Name	General Electric Co
Entity Central Index Key	0000040545
Amendment Flag	false
Entity Incorporation, State or Country Code	NY
Entity File Number	001-00035
Entity Tax Identification Number	14-0689340
Entity Address, Address Line One	5 Necco Street
Entity Address, City or Town	Boston,
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02210
City Area Code	617
Local Phone Number	443-3000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common stock, par value $0.06 per share
Trading Symbol	GE
Security Exchange Name	NYSE
Floating Rate Notes Due 2020 [Member]
Entity Information [Line Items]
Title of 12(b) Security	Floating Rate Notes due 2020
Trading Symbol	GE 20E
Security Exchange Name	NYSE
0.375% Notes Due 2022 [Member]
Entity Information [Line Items]
Title of 12(b) Security	0.375% Notes due 2022
Trading Symbol	GE 22A
Security Exchange Name	NYSE
1.250% Notes Due 2023 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.250% Notes due 2023
Trading Symbol	GE 23E
Security Exchange Name	NYSE
0.875% Notes Due 2025 [Member]
Entity Information [Line Items]
Title of 12(b) Security	0.875% Notes due 2025
Trading Symbol	GE 25
Security Exchange Name	NYSE
1.875% Notes Due 2027 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.875% Notes due 2027
Trading Symbol	GE 27E
Security Exchange Name	NYSE
1.500% Notes Due 2029 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.500% Notes due 2029
Trading Symbol	GE 29
Security Exchange Name	NYSE
7.5% Guaranteed Subordinated Notes Due 2035 [Member]
Entity Information [Line Items]
Title of 12(b) Security	7 1/2% Guaranteed Subordinated Notes due 2035
Trading Symbol	GE /35
Security Exchange Name	NYSE
2.125% Notes Due 2037 [Member]
Entity Information [Line Items]
Title of 12(b) Security	2.125% Notes due 2037
Trading Symbol	GE 37
Security Exchange Name	NYSE

XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 10 95 1 false 9 0 false 0 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.ge.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports biopharmaproforma8-k.htm biopharmaproformaexhib.htm ge-20200306.xsd ge-20200306_cal.xml ge-20200306_def.xml ge-20200306_lab.xml ge-20200306_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end ZIP 15 0000040545-20-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000040545-20-000012-xbrl.zip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end XML 16 biopharmaproforma8-k_htm.xml IDEA: XBRL DOCUMENT 0000040545 2020-03-31 2020-03-31 0000040545 ge:A1.875NotesDue2027Member 2020-03-31 2020-03-31 0000040545 ge:A1.500NotesDue2029Member 2020-03-31 2020-03-31 0000040545 ge:FloatingRateNotesDue2020Member 2020-03-31 2020-03-31 0000040545 ge:A1.250NotesDue2023Member 2020-03-31 2020-03-31 0000040545 us-gaap:CommonStockMember 2020-03-31 2020-03-31 0000040545 ge:A0.875NotesDue2025Member 2020-03-31 2020-03-31 0000040545 ge:A2.125NotesDue2037Member 2020-03-31 2020-03-31 0000040545 ge:A7.5GuaranteedSubordinatedNotesDue2035Member 2020-03-31 2020-03-31 0000040545 ge:A0.375NotesDue2022Member 2020-03-31 2020-03-31 false 0000040545 8-K 2020-03-31 General Electric Co NY 001-00035 14-0689340 5 Necco Street Boston, MA 02210 617 443-3000 false false false false Common stock, par value $0.06 per share GE NYSE Floating Rate Notes due 2020 GE 20E NYSE 0.375% Notes due 2022 GE 22A NYSE 1.250% Notes due 2023 GE 23E NYSE 0.875% Notes due 2025 GE 25 NYSE 1.875% Notes due 2027 GE 27E NYSE 1.500% Notes due 2029 GE 29 NYSE 7 1/2% Guaranteed Subordinated Notes due 2035 GE /35 NYSE 2.125% Notes due 2037 GE 37 NYSE false